We are analyzing https://link.springer.com/article/10.1007/s00277-010-1118-7.

Title:
Leukemia stem cells | Annals of Hematology
Description:
Leukemia-initiating cells (LICs) or leukemia stem cells (LSCs) are defined by their ability to form tumors after xenotransplantation in immunodeficient mice and appear to be rare in most human leukemias. In various leukemias, only small subpopulations of cells can transfer disease upon transplantation into immunocompromised NOD/SCID mice, and markers that distinguish the leukemogenic cancer cells from the bulk populations of non-leukemogenic cells have been identified. However, the phenotype of LICs is heterogeneous: it is variable for the different types of acute myeloid leukemias; cells with different membrane phenotype can act as LICs in each B-acute lymphoid leukemia; LICs change during the evolution of chronic myeloid leukemia from the chronic to the acute phase. There is a general consensus that the identification and characterization of leukemic stem cells might lead to the identification of new therapeutic targets and, through this way, to more effective treatments by focusing therapy on the most malignant cells.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Education
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't tell how the site generates income.

While profit motivates many websites, others exist to inspire, entertain, or provide valuable resources. Websites have a variety of goals. And this might be one of them. Link.springer.com might have a hidden revenue stream, but it's not something we can detect.

Keywords {🔍}

google, scholar, article, cas, pubmed, cells, stem, leukemia, cell, blood, myeloid, acute, human, hematopoietic, nature, leukemic, mice, chronic, progenitor, cancer, eaves, myelogenous, usa, expression, med, engraftment, proc, acad, sci, aml, jak, marrow, dick, lymphoblastic, leukemiainitiating, natl, progenitors, holyoake, myeloproliferative, leukemias, nodscid, targeting, bone, wang, lee, potential, van, normal, cml, imatinib,

Topics {✒️}

female nod/scid/il-2rgc-null recipients nod/scid-beta2-microglobulin-deficient mice anti-cd38 antibody-mediated clearance accelerates k-ras-initiated leukemia cd34+cd38−-stem cell compartment nod/scid/gamma null mouse month download article/chapter nod/scid repopulating cells cd34+cd38−cd19+ cells intra-bone marrow injection philadelphia-positive stem cells pro-b-cell development pathways adult stem cells scid-repopulating cell activity long-term repopulating potential repopulating immune-deficient mice hematopoietic progenitor/stem cells nod/scid assay reflects candidate leukemia-initiating cells mll-af4 fusion gene philadelphia chromosome-positive cells nod-scid mice reveals selective long-term elimination pml-rar-induced leukemogenesis bcr-abl-induced leukemias jak2v617f-positive myeloproliferative disorders b-acute lymphoid leukemia monoclonal antibody-mediated targeting bcr-abl targeted therapies nod/scxid mice engineered cml stem/progenitor cells pml-rarα initiates leukemia immunocompromised nod/scid mice nod/scid mice transgenic bone marrow hematopoietic bcr-abl enhances differentiation short-lived myeloid progenitors human stem cells genome-wide variation analysis beta2 microglobulin-deficient including cd34+38− cells cd34+cd38+cd19+ wnt/β-catenin pathway hematopoietic stem cells time-limited reconstitution potential parthenolide-induced apoptosis leukemic stem cells leukemia stem cells mutated nucleophosmin reside nod/scid gamma

Questions {❓}

Greaves M (2010) Cancer stem cells: back to Darwin?
Passegué E, Jamieson CHM, Aille SLE, Weissman IL (2003) Normal and leukemic hemopoiesis: are leukemias a stem cell disorder or reacquisition of stem cell characteristics?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Leukemia stem cells
         description:Leukemia-initiating cells (LICs) or leukemia stem cells (LSCs) are defined by their ability to form tumors after xenotransplantation in immunodeficient mice and appear to be rare in most human leukemias. In various leukemias, only small subpopulations of cells can transfer disease upon transplantation into immunocompromised NOD/SCID mice, and markers that distinguish the leukemogenic cancer cells from the bulk populations of non-leukemogenic cells have been identified. However, the phenotype of LICs is heterogeneous: it is variable for the different types of acute myeloid leukemias; cells with different membrane phenotype can act as LICs in each B-acute lymphoid leukemia; LICs change during the evolution of chronic myeloid leukemia from the chronic to the acute phase. There is a general consensus that the identification and characterization of leukemic stem cells might lead to the identification of new therapeutic targets and, through this way, to more effective treatments by focusing therapy on the most malignant cells.
         datePublished:2010-11-25T00:00:00Z
         dateModified:2010-11-25T00:00:00Z
         pageStart:245
         pageEnd:271
         sameAs:https://doi.org/10.1007/s00277-010-1118-7
         keywords:
            Leukemia
            Acute leukemia
            Myelodysplasia
            Myeloproliferative disorders
            Stem cells
            Hematology
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00277-010-1118-7/MediaObjects/277_2010_1118_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00277-010-1118-7/MediaObjects/277_2010_1118_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00277-010-1118-7/MediaObjects/277_2010_1118_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00277-010-1118-7/MediaObjects/277_2010_1118_Fig4_HTML.gif
         isPartOf:
            name:Annals of Hematology
            issn:
               1432-0584
               0939-5555
            volumeNumber:90
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Ugo Testa
               affiliation:
                     name:Istituto Supeirore di Sanità
                     address:
                        name:Department of Hematology, Oncology and Molecular Medicine, Istituto Supeirore di Sanità, Rome, Italy
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Leukemia stem cells
      description:Leukemia-initiating cells (LICs) or leukemia stem cells (LSCs) are defined by their ability to form tumors after xenotransplantation in immunodeficient mice and appear to be rare in most human leukemias. In various leukemias, only small subpopulations of cells can transfer disease upon transplantation into immunocompromised NOD/SCID mice, and markers that distinguish the leukemogenic cancer cells from the bulk populations of non-leukemogenic cells have been identified. However, the phenotype of LICs is heterogeneous: it is variable for the different types of acute myeloid leukemias; cells with different membrane phenotype can act as LICs in each B-acute lymphoid leukemia; LICs change during the evolution of chronic myeloid leukemia from the chronic to the acute phase. There is a general consensus that the identification and characterization of leukemic stem cells might lead to the identification of new therapeutic targets and, through this way, to more effective treatments by focusing therapy on the most malignant cells.
      datePublished:2010-11-25T00:00:00Z
      dateModified:2010-11-25T00:00:00Z
      pageStart:245
      pageEnd:271
      sameAs:https://doi.org/10.1007/s00277-010-1118-7
      keywords:
         Leukemia
         Acute leukemia
         Myelodysplasia
         Myeloproliferative disorders
         Stem cells
         Hematology
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00277-010-1118-7/MediaObjects/277_2010_1118_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00277-010-1118-7/MediaObjects/277_2010_1118_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00277-010-1118-7/MediaObjects/277_2010_1118_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00277-010-1118-7/MediaObjects/277_2010_1118_Fig4_HTML.gif
      isPartOf:
         name:Annals of Hematology
         issn:
            1432-0584
            0939-5555
         volumeNumber:90
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Ugo Testa
            affiliation:
                  name:Istituto Supeirore di Sanità
                  address:
                     name:Department of Hematology, Oncology and Molecular Medicine, Istituto Supeirore di Sanità, Rome, Italy
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Annals of Hematology
      issn:
         1432-0584
         0939-5555
      volumeNumber:90
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Istituto Supeirore di Sanità
      address:
         name:Department of Hematology, Oncology and Molecular Medicine, Istituto Supeirore di Sanità, Rome, Italy
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Ugo Testa
      affiliation:
            name:Istituto Supeirore di Sanità
            address:
               name:Department of Hematology, Oncology and Molecular Medicine, Istituto Supeirore di Sanità, Rome, Italy
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Hematology, Oncology and Molecular Medicine, Istituto Supeirore di Sanità, Rome, Italy
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(535)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.43s.

LINK . SPRINGER . COM {}